R&D

R&D is
the heart of our mission to develop global medicines for incurable diseases.

Pipeline for New Medicine

New Bio Medicine

Statement of Financial Position
Project Title Effective in R&D Non-clinical Clinical Trial Phase 1 Clinical Trial Phase 2 Clinical Trial Phase 3
HL161

Novel Anti-FcRn Antibody with Molecular Improvement

DownLoad
autoimmune diseases
완료
완료
HL036
(jointly developed with Daewoong Pharmaceutical)

Anti-TNF New Bio Ophthalmic Solution

DownLoad
dry eye disease
완료
완료
완료
HL186

Immuno-oncology

recurrent/
intractable cancer
완료
HL187

Immuno-oncology

recurrent/
intractable cancer
완료

New Advanced Medicine

Statement of Financial Position
Project Title Effective in R&D Non-clinical Clinical Trial Phase 1 Clinical Trial Phase 2 Clinical Trial Phase 3
HL040

Advanced Composite Medicine for Hypertension-Dyslipidemia

ypertension
·
hyperlipidemia
완료
완료
완료
완료
완료
HL068

Advanced Composite Medicine for Hypertension

hypertension
완료
완료
완료
완료
완료
HL018

Advanced Medicine with verified safety for obesity cure

obesity
완료

New Synthetic Medicine

Statement of Financial Position
Project Title Effective in R&D Non-clinical Clinical Trial Phase 1 Clinical Trial Phase 2 Clinical Trial Phase 3
IM156
(developed by IMMUNOMET)

Cancer metabolism

anticancer
완료
완료